Peficitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Peficitinib
Accession Number
DB11708
Type
Small Molecule
Groups
Investigational
Description

Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics, Drug Interactions, Colitis, Ulcerative, and RHEUMATOID ARTHRITIS, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
ASP-015K / ASP015K / JNJ-54781532
Categories
UNII
HPH1166CKX
CAS number
944118-01-8
Weight
Average: 326.4
Monoisotopic: 326.174275964
Chemical Formula
C18H22N4O2
InChI Key
DREIJXJRTLTGJC-RRBRBRQDSA-N
InChI
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14-,18+
IUPAC Name
4-{[(1R,2s,3S,5r)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
SMILES
NC(=O)C1=CN=C2NC=CC2=C1N[C@H]1[C@H]2CC3C[C@@H]1C[C@@](O)(C3)C2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Peficitinib.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Peficitinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Peficitinib.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Peficitinib.
ActeosideThe risk or severity of adverse effects can be increased when Peficitinib is combined with Acteoside.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Peficitinib.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Peficitinib.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Peficitinib.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Peficitinib.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Peficitinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
57928403
PubChem Substance
347828073
ChemSpider
58827925
Wikipedia
Janus_kinase_inhibitor

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableBioavailability of ASP015K / Food Effect of ASP015K / Healthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedNot AvailableBioavailability of ASP015K / Healthy Volunteers / Pharmacokinetics of ASP015K2
1CompletedNot AvailableDrug Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of ASP015K2
1CompletedNot AvailableFood Effect / Healthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamics / Pharmacokinetics of ASP015K1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP015K3
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP015K and Midazolam1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP015K and Tacrolimus1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of ASP015K2
1CompletedOtherHealthy Volunteers1
1CompletedOtherHealthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedOtherRheumatoid Arthritis1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPatients With Impaired Hepatic Function1
1CompletedTreatmentPatients With Impaired Renal Function1
1RecruitingBasic ScienceHealthy Volunteers1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis4
2CompletedTreatmentUlcerative Colitis1
3CompletedTreatmentRheumatoid Arthritis3
3RecruitingTreatmentRheumatoid Arthritis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.159 mg/mLALOGPS
logP1.62ALOGPS
logP1.06ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.85ChemAxon
pKa (Strongest Basic)5.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area104.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity91.34 m3·mol-1ChemAxon
Polarizability49.65 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyridines
Sub Class
Not Available
Direct Parent
Pyrrolopyridines
Alternative Parents
Pyridinecarboxamides / Secondary alkylarylamines / Aminopyridines and derivatives / Vinylogous amides / Tertiary alcohols / Pyrroles / Heteroaromatic compounds / Primary carboxylic acid amides / Cyclic alcohols and derivatives / Amino acids and derivatives
show 4 more
Substituents
Pyridinecarboxamide / Pyridine carboxylic acid or derivatives / Pyrrolopyridine / Aminopyridine / Secondary aliphatic/aromatic amine / Pyridine / Cyclic alcohol / Pyrrole / Heteroaromatic compound / Tertiary alcohol
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:41 / Updated on March 01, 2020 20:58

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates